Search hospitals > Wisconsin > Milwaukee
Ascension Columbia Saint Mary's Hospital - Milwaukee
Claim this profileMilwaukee, Wisconsin 53211
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
108 reported clinical trials
7 medical researchers
Summary
Ascension Columbia Saint Mary's Hospital - Milwaukee is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Ascension Columbia Saint Mary's Hospital - Milwaukee is involved with conducting 108 clinical trials across 253 conditions. There are 7 research doctors associated with this hospital, such as Jonathan S. Treisman, Francis J. Cuevas, Shannon Offerman, and Ranveer Nand.Area of expertise
1Cancer
Global LeaderStage II
Stage I
Stage IV
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Jonathan S. TreismanAscension Saint Elizabeth Hospital4 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
15 reported clinical trials
32 drugs studied
Francis J. CuevasAscension Southeast Wisconsin Hospital - Elmbrook Campus7 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
11 reported clinical trials
24 drugs studied
Shannon OffermanAscension Southeast Wisconsin Hospital - Elmbrook Campus8 years of reported clinical research
Studies Adenocarcinoma
Studies Prostate Adenocarcinoma
9 reported clinical trials
29 drugs studied
Ranveer NandAscension Columbia Saint Mary's Hospital - Milwaukee2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
8 reported clinical trials
19 drugs studied
Clinical Trials running at Ascension Columbia Saint Mary's Hospital - Milwaukee
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Prostate Cancer
Multiple Myeloma
Pancreatic Cancer
Plasma Cell Neoplasms
ALK Gene Rearrangement
Prostate Adenocarcinoma
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ascension Columbia Saint Mary's Hospital - Milwaukee?
Ascension Columbia Saint Mary's Hospital - Milwaukee is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Ascension Columbia Saint Mary's Hospital - Milwaukee is involved with conducting 108 clinical trials across 253 conditions. There are 7 research doctors associated with this hospital, such as Jonathan S. Treisman, Francis J. Cuevas, Shannon Offerman, and Ranveer Nand.